The British National Institute of Health and Care Excellence (NICE) recommends reimbursement of FSL for young and adult T1DM patients and for patients with T2DM who use intensive insulin therapy and experience recurrent or severe hypoglycemia [17–19]. The gene discussed is INS; the disease is Hypoglycemia.